Clinical Trials
31 trialsBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
ELEGANT
Stemline Therapeutics, Inc.
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
COMBINE-01
European Institute of Oncology
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Circulating Tumor DNA
Yale University
ELCIN
Stemline Therapeutics, Inc.
ADAPTela
West German Study Group
SOLTI-2104
SOLTI Breast Cancer Research Group
ERADICATE
Dana-Farber Cancer Institute
ELECTRA
Stemline Therapeutics, Inc.
ADELA
MedSIR
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Criterium, Inc.
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
CAPELA
Dana-Farber Cancer Institute
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
ELEVATE
Stemline Therapeutics, Inc.
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
ELEMENT
GBG Forschungs GmbH
POP-ELA
Gustave Roussy, Cancer Campus, Grand Paris
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
EMERALD
Stemline Therapeutics, Inc.
HELP
Azienda Ospedaliero-Universitaria Careggi
ELONA
Context Therapeutics Inc.
A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Context Therapeutics Inc.
ELIPSE
SOLTI Breast Cancer Research Group
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Stemline Therapeutics, Inc.
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
Stemline Therapeutics, Inc.